PCSK6-mediated corin activation is essential for normal blood pressure

Nature Medicine

Volumn 21, Issue 9, 2015, Pages 1048-1053

  Chen, Shenghan ^a,e   Cao, Pengxiu ^a,f   Dong, Ningzheng ^b,c   Peng, Jianhao ^a   Zhang, Chunyi ^a,g   Wang, Hao ^a   Zhou, Tiantian ^b   Yang, Junhua ^c   Zhang, Yue ^b   Martelli, Elizabeth E ^a   Naga Prasad, Sathyamangla V ^a   Miller, Rachel E ^d   Malfait, Anne Marie ^d   Zhou, Yiqing ^b   Wu, Qingyu ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Jiangxi Provincial People's Hospital   (China)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORIN PROTEIN; PCSK6 PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CORIN PROTEIN, HUMAN; PCSK6 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME PURIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; C57BL MOUSE; GENETICS; HAMSTER; HEK293 CELL LINE; MUTATION; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; CRICETINAE; HEK293 CELLS; HUMANS; HYPERTENSION; MICE; MICE, INBRED C57BL; MUTATION; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84941024139     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3920     Document Type: Article

References (49)

1. Go, A.S. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Lifton, R.P., Gharavi, A.G. & Geller, D.S. Molecular mechanisms of human hypertension. Cell 104, 545-556 (2001).
3. Oparil, S., Zaman, M.A. & Calhoun, D.A. Pathogenesis of hypertension. Ann. Intern. Med. 139, 761-776 (2003).
4. Yan, W., Wu, F., Morser, J. & Wu, Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. USA 97, 8525-8529 (2000).
5. Cui, Y. et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 484, 246-250 (2012).
6. Dong, N. et al. Corin mutation R539C from hypertensive patients impairs zymogen activation and generates an inactive alternative ectodomain fragment. J. Biol. Chem. 288, 7867-7874 (2013).
7. Dries, D.L. et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 112, 2403-2410 (2005).
8. Rame, J.E. et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension 49, 857-864 (2007).
9. Wang, W. et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ. Res. 103, 502-508 (2008).
10. Seidah, N.G., Sadr, M.S., Chretien, M. & Mbikay, M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J. Biol. Chem. 288, 21473-21481 (2013).
11. Guyton, A.C. Blood pressure control-special role of the kidneys and body fluids. Science 252, 1813-1816 (1991).
12. Mullins, L.J., Bailey, M.A. & Mullins, J.J. Hypertension, kidney, and transgenics: a fresh perspective. Physiol. Rev. 86, 709-746 (2006).
13. Cowley, A.W. Jr. The genetic dissection of essential hypertension. Nat. Rev. Genet. 7, 829-840 (2006).
14. McGrath, M.F., de Bold, M.L. & de Bold, A.J. The endocrine function of the heart. Trends Endocrinol. Metab. 16, 469-477 (2005).
15. Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet. 41, 348-353 (2009).
16. Barbato, E. et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J. Am. Coll. Cardiol. 59, 1763-1770 (2012).
17. Cannone, V. et al. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension 62, 860-865 (2013).
18. Hodgson-Zingman, D.M. et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N. Engl. J. Med. 359, 158-165 (2008).
19. Lynch, A.I., Claas, S.A. & Arnett, D.K. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr. Hypertens. Rep. 11, 35-42 (2009).
20. Yan, W., Sheng, N., Seto, M., Morser, J. & Wu, Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J. Biol. Chem. 274, 14926-14935 (1999).
21. Jiang, J. et al. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J. Biol. Chem. 286, 10066-10072 (2011).
22. Rockwell, N.C., Krysan, D.J., Komiyama, T. & Fuller, R.S. Precursor processing by kex2/furin proteases. Chem. Rev. 102, 4525-4548 (2002).
23. Beaubien, G. et al. The distinct gene expression of the pro-hormone convertases in the rat heart suggests potential substrates. Cell Tissue Res. 279, 539-549 (1995).
24. Wang, W. et al. Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. Kidney Int. 82, 26-33 (2012).
25. Constam, D.B. & Robertson, E.J. SPC4/PACE4 regulates a TGFβ signaling network during axis formation. Genes Dev. 14, 1146-1155 (2000).
26. Wang, W. et al. Salt-sensitive hypertension and cardiac hypertrophy in transgenic mice expressing a corin variant identified in blacks. Hypertension 60, 1352-1358 (2012).
27. Dong, N. et al. Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. J. Biol. Chem. 289, 17909-17916 (2014).
28. Taneda, H., Andoh, K., Nishioka, J., Takeya, H. & Suzuki, K. Blood coagulation factor Xa interacts with a linear sequence of the kringle 2 domain of prothrombin. J. Biochem. 116, 589-597 (1994).
29. Guipponi, M. et al. The transmembrane serine protease (TMPRSS3) mutated in deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro. Hum. Mol. Genet. 11, 2829-2836 (2002).
30. Chan, J.C. et al. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc. Natl. Acad. Sci. USA 102, 785-790 (2005).
31. Chen, H.H. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!. J. Am. Coll. Cardiol. 49, 1089-1091 (2007).
32. Chen, S. et al. Protease corin expression and activity in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 299, H1687-H1692 (2010).
33. Dries, D.L. Process matters: Emerging concepts underlying impaired natriuretic peptide system function in heart failure. Circ Heart Fail 4, 107-110 (2011).
34. Gladysheva, I.P. et al. Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension 61, 327-332 (2013).
35. Li, J.P. et al. The association between paired basic amino acid cleaving enzyme 4 gene haplotype and diastolic blood pressure. Chin. Med. J. (Engl.) 117, 382-388 (2004).
36. Cohen, J.C. & Hobbs, H.H. Genetics. Simple genetics for a complex disease. Science 340, 689-690 (2013).
37. Horton, J.D., Cohen, J.C. & Hobbs, H.H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50 (suppl.), S172-S177 (2009).
38. Seidah, N.G., Awan, Z., Chretien, M. & Mbikay, M. PCSK9: a key modulator of cardiovascular health. Circ. Res. 114, 1022-1036 (2014).
39. Davidson, M.H. Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat. Rev. Cardiol. 10, 618-619 (2013).
40. Seidah, N.G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383 (2012).
41. Liao, X., Wang, W., Chen, S. & Wu, Q. Role of glycosylation in corin zymogen activation. J. Biol. Chem. 282, 27728-27735 (2007).
42. Knappe, S., Wu, F., Masikat, M.R., Morser, J. & Wu, Q. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J. Biol. Chem. 278, 52363-52370 (2003).
43. Wu, F., Yan, W., Pan, J., Morser, J. & Wu, Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J. Biol. Chem. 277, 16900-16905 (2002).
44. Qi, X., Jiang, J., Zhu, M. & Wu, Q. Human corin isoforms with different cytoplasmic tails that alter cell surface targeting. J. Biol. Chem. 286, 20963-20969 (2011).
45. Dinter, A. & Berger, E.G. Golgi-disturbing agents. Histochem. Cell Biol. 109, 571-590 (1998).
46. Malfait, A.M. et al. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann. Rheum. Dis. 71, 1042-1048 (2012).
47. Jiang, J., Pristera, N., Wang, W., Zhang, X. & Wu, Q. Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. Clin. Chem. 56, 959-966 (2010).
48. Vasudevan, N.T. et al. Gβ-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor a-induced cardiac β-adrenergic receptor dysfunction. Circulation 128, 377-387 (2013).
49. Dong, N. et al. Plasma-soluble corin in patients with heart failure. Circ Heart Fail 3, 207-211 (2010).